|
Martin Streeter has more than 20 years of experience in bioinformatics, clinical software R&D, and knowledge management. He has designed and implemented enhanced procedures and quality improvement strategies that support the implementation of FDA 21 CFR Part 11 regulations. Most recently, he was a Venture Partner with Zero Stage Capital. Previously, he was CEO of Invantage, Inc., a venture-backed software company focused on improving the launch of clinical trials (since acquired by Perceptive Informatics, a subsidiary of PAREXEL International). Earlier, he was involved with the marketing of expert medical procedure cost containment systems for Health Payment Review. He started his career as part of the original BBN Clintrial® team and went on to product development at PAREXEL. He holds a B.A. in Molecular Cellular Developmental Biology from the University of Colorado and an M.S. in Biometry/Biostatistics from Case Western Reserve University. | 